Anifrolumab (Saphnelo) listed in NS

March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024.

The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is posted.

Lupus Blog Articles:

Mental Health and Lupus: A Global Perspective

Read

Biogen Lupus Research | New Treatments in Development

Read

Living with Lupus: Yaneisy-Nynoska Tremblay’s Story | Lupus Canada

Read